Potential to use Deoxymabs to treat autoimmune diseases 

Quarterly Activities Report and 4C | 31 December 2023

GMP Production of PAT-DX1 Next Quarter

Patrys Receives R&D Tax Incentive Refund

Quarterly Activities Report and 4C Quarterly Cash Flow Report

Data to be presented at leading brain cancer conference

Retirement of Non-Executive Director

Patrys FY23 Annual Report

Quarterly Activities Report and 4C | 30 June 2023

QUARTERLY ACTIVITIES REPORT & 4C | 31 March 2023